Ticker > Company >

Cipla share price

Cipla Ltd.

NSE: CIPLA BSE: 500087 SECTOR: Pharmaceuticals & Drugs  464k   3k   513

1508.10
-26.30 (-1.71%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 1537.95

Today's Low

₹ 1504.05

52 Week High

₹ 1702

52 Week Low

₹ 1192.85

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

121796.04 Cr.

Enterprise Value

121462.84 Cr.

No. of Shares

80.76 Cr.

P/E

28.77

P/B

4.18

Face Value

₹ 2

Div. Yield

0.86 %

Book Value (TTM)

₹  360.74

CASH

333.2 Cr.

DEBT

0 Cr.

Promoter Holding

30.92 %

EPS (TTM)

₹  52.42

Sales Growth

15.54%

ROE

14.14 %

ROCE

18.88%

Profit Growth

73.23 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Cipla Ltd.

Paracip Montair LC Cipmolnu Dytor Moxicip Novamox Lametec Ibugesic Fourderm CPink CDense Productiv nicotex ActivKids immuno boosters cofsils CIPHANDS OMNIGEL CORYX BRONCOL COUGH SYRUP Cheston Asthalin Norflox Urimax CIPREMI

Index Presence

The company is present in 39 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year15.54%
3 Year13.61%
5 Year6.02%

Profit Growth

1 Year62.22%
3 Year18.21%
5 Year16.64%

ROE%

1 Year14.14%
3 Year12.29%
5 Year12.37%

ROCE %

1 Year18.88%
3 Year16.59%
5 Year16.6%

Debt/Equity

0

Price to Cash Flow

32.68

Interest Cover Ratio

245.2948

CFO/PAT (5 Yr. Avg.)

1.14576472967456

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 30.92 0.00
Jun 2024 30.91 0.00
Mar 2024 33.47 0.00
Dec 2023 33.47 0.00
Sep 2023 33.47 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 22.01551196298% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 245.2948.
  • The Company has been maintaining an effective average operating margins of 23.1326212942778% in the last 5 years.
  • Company’s PEG ratio is 0.393050305076677.
  • The company has an efficient Cash Conversion Cycle of -29.628 days.
  • Company has a healthy liquidity position with current ratio of 5.191.
  • The company has a good cash flow management; CFO/PAT stands at 1.14576472967456.

 Limitations

  • The company has shown a poor revenue growth of 13.6102020134256% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 4234.44 4381.33 4036.66 4501.05 4775.03
Total Expenditure 3009.06 3025.47 3208.77 3141.19 3336.99
Operating Profit 1225.38 1355.86 827.89 1359.86 1438.04
Other Income 205.09 168.98 538.61 213.52 289.14
Interest 6.61 9.06 5.45 5.07 3
Depreciation 179.81 135.02 136.81 137.86 145.71
Exceptional Items 0 0 0 0 0
Profit Before Tax 1244.05 1380.76 1224.24 1430.45 1578.47
Tax 328.51 363 242.21 374.51 400.31
Profit After Tax 915.54 1017.76 982.03 1055.94 1178.16
Adjusted EPS (Rs) 11.34 12.61 12.16 13.08 14.59

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 12659.15 11302.71 15380.82 14345.34 16574.34
Total Expenditure 9972.77 8235.3 11669.59 11000.23 12090.19
Operating Profit 2686.38 3067.41 3711.23 3345.11 4484.15
Other Income 913.76 230.28 666.7 464.57 1070.66
Interest 36.05 45.07 26.93 22.27 20.25
Depreciation 599.78 468.62 546.62 595.91 587.59
Exceptional Items 0 0 0 -185.9 0
Profit Before Tax 2964.31 2784 3804.38 3005.6 4946.97
Tax 646.14 739.35 921.8 861.54 1232.78
Net Profit 2318.17 2468.28 2957.93 2513.47 4077.25
Adjusted EPS (Rs.) 28.75 25.35 35.73 26.56 46

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 161.25 161.29 161.36 161.43 161.47
Total Reserves 17241.71 19766.27 22352.19 24476.66 27812.45
Borrowings 0 0 0 0 0
Other N/C liabilities 383.41 344.24 276.16 258.64 217.06
Current liabilities 2619.29 2691.94 2632.37 2699.74 2862.25
Total Liabilities 20405.66 22963.74 25449.05 27596.47 31053.23
Assets
Net Block 4024.54 3942.66 3846.57 3747.28 3603.14
Capital WIP 255.73 275.04 186.26 441.53 580.9
Intangible WIP 64 80.07 81.42 62.72 89.37
Investments 6355.32 7720.99 8934.88 9137.91 9410.17
Loans & Advances 516.63 596.1 555.68 748.77 1904.67
Other N/C Assets 164.72 158.13 509.2 87.13 607.14
Current Assets 9024.72 10190.75 11335.04 13371.13 14857.84
Total Assets 20405.66 22963.74 25449.05 27596.47 31053.23
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2964.31 3350.66 3905.08 3685.17 5432.14
Adjustment -35.73 520.41 73.26 269.57 -342.91
Changes in Assets & Liabilities -245.46 541.19 -270.88 164.57 -138.3
Tax Paid -664.98 -951.95 -934.03 -1084.26 -1224.16
Operating Cash Flow 2018.14 3460.31 2773.43 3035.05 3726.77
Investing Cash Flow -1127.18 -3361.33 -2464.14 -2758.09 -2882.9
Financing Cash Flow -693.89 -65.8 -426.72 -424.77 -708.83
Net Cash Flow 197.07 33.18 -117.43 -147.81 135.04

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 33.47 33.47 33.47 30.91 30.92
kamil hamied 1.36 1.36 1.36 1.36 1.36
m k hamied - 3.46 - 3.45 3.46
rumana hamied 1.23 1.23 1.23 0.61 0.61
samina hamied 2.22 2.22 2.22 1.11 1.11
sophie ahmed - 5.71 5.71 5.70 5.71
yusuf khwaja hameid 18.68 18.68 18.68 18.67 18.68
m k hamied - - 3.46 - -
okasa pharma private limi... 0.02 0.02 0.02 - -
shirin hamied 0.79 0.79 0.79 - -
mustafa khwaja hamied 3.46 - - - -
sophie ahmed 5.71 - - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 66.53 66.53 66.53 69.09 69.08
government pension fund g... 2.75 2.91 2.36 2.08 2.11
hdfc mutual fund-hdfc arb... - - - - 5.11
icici prudential equity a... - - - - 1.11
investor education and pr... - - - 0.33 0.33
kotak equity hybrid - - - - 1.03
lici money plus balanced ... - - - - 3.13
sbi arbitrage opportuniti... - 4.68 - - 2.75
uti nifty 50 index fund - - - - 1.04
hdfc mutual fund - hdfc f... - - - 4.94 -
icici prudential s&p bse ... - - - 1.12 -
lic 2.88 3.46 3.67 3.53 -
nps - - - 1.58 -
sbi long term equity fund... - - - 3.24 -
uti nifty index fund - - - 1.01 -
hdfc mutual fund 3.60 - 4.47 - -
investor education and pr... 0.32 0.33 0.33 - -
nps trust 1.91 - 1.66 - -
sbi mutual fund 4.68 - 4.23 - -
hdfc trustee company ltd.... - 4.32 - - -
icici prudential nifty50 ... - 1.02 - - -
nps trust - 1.73 - - -
uti balanced advantage fu... - 1.12 - - -
government of singapore 1.02 - - - -
icici prudential mutual f... 1.06 - - - -
kotak mutual fund 1.07 - - - -
uti 1.14 - - - -

Ratings & Research Reports

Company Presentations

Company News

Cipla informs about disclosure 2 Dec, 5:36 PM Cipla informs about disclosures 28 Nov, 11:55 AM USFDA concludes inspection at Cipla’s manufacturing facility in Bengaluru 14 Nov, 9:40 AM Cipla informs about newspaper publication 29 Oct, 5:19 PM Cipla’s consolidated net profit rises 13% in Q2FY25 29 Oct, 3:51 PM Cipla - Quaterly Results 29 Oct, 2:19 PM Cipla - Quaterly Results 29 Oct, 2:19 PM Cipla - Quaterly Results 29 Oct, 2:19 PM Cipla’s arm to acquire 6.9% stake held by Jiangsu Xidi Pharmaceuticals in China-based unit 26 Sep, 12:44 PM Cipla informs about corrigendum 4 Sep, 9:50 AM Cipla reports 18% rise in Q1 consolidated net profit 29 Jul, 10:41 AM Cipla informs about disclosure 26 Jul, 4:48 PM Cipla - Quaterly Results 26 Jul, 3:04 PM Cipla - Quaterly Results 26 Jul, 3:04 PM Cipla - Quaterly Results 26 Jul, 3:04 PM Cipla informs about disclosure 26 Jul, 12:36 PM USFDA classifies Cipla’s Patalganga manufacturing facility as Voluntary Action Indicated 25 Jun, 6:21 PM Cipla informs about updates 25 Jun, 4:23 PM USFDA conducts inspection at Cipla’s manufacturing facility in Goa 22 Jun, 12:22 PM Cipla’s arm to invest additional EUR 3 million in Ethris GmbH 18 Jun, 3:42 PM Cipla informs about disclosure 22 May, 12:56 PM Cipla gets USFDA’s final nod for Lanreotide injection 22 May, 11:42 AM Cipla inks pact to make additional investment in Achira Labs 16 May, 10:58 AM Cipla’s promoters sell 2.53% stake in company 15 May, 4:59 PM Cipla informs about clarification 15 May, 11:06 AM Cipla reports 79% rise in Q4 consolidated net profit 10 May, 3:26 PM Cipla - Quaterly Results 10 May, 2:30 PM Cipla - Quaterly Results 10 May, 2:30 PM Cipla - Quaterly Results 10 May, 2:30 PM Cipla's arm acquires business undertaking from Ivia Beaute 29 Apr, 10:30 AM Cipla informs about allotment of equity shares 16 Apr, 2:48 PM Cipla's arm signs agreement for acquisition of business undertaking from Ivia Beaute 16 Apr, 9:20 AM USFDA concludes routine cGMP inspection at Cipla’s manufacturing facility in Patalganga 5 Apr, 9:24 AM Cipla partners with Sanofi India 27 Mar, 10:46 AM Cipla’s arm completes sale of entire shareholding in Wellthy 7 Mar, 9:25 AM Cipla transfers Generics Business Undertaking to Cipla Pharma and Life Sciences 2 Mar, 9:33 AM Cipla secures approval to market novel antibiotic plazomicin in India 27 Feb, 4:57 PM Cipla ties up with CSIR-CDRI 16 Feb, 10:41 AM Cipla’s arm completes acquisition of 100% equity stake in Actor Pharma 8 Feb, 9:20 AM Cipla acquires additional stake in GoApptiv 3 Feb, 10:25 AM Cipla’s arms incorporate wholly owned subsidiary in Mexico 23 Jan, 3:12 PM Cipla reports 32% rise in Q3 consolidated net profit 23 Jan, 2:26 PM Cipla - Quaterly Results 22 Jan, 6:49 PM Cipla - Quaterly Results 22 Jan, 6:49 PM Cipla informs about acquisition 6 Jan, 12:44 PM Cipla’s arm to incorporate JV Company in USA 6 Jan, 10:53 AM Cipla informs about revised press release 16 Dec, 2:22 PM Cipla to further invest Rs 42 crore in GoApptiv 15 Dec, 12:30 PM Cipla's arm recalls one lot of Vigabatrin for oral solution USP 500 mg 11 Dec, 9:50 AM Cipla’s arm acquires additional 15.10% stake in Cipla Maroc SA 28 Nov, 11:53 AM

Cipla Stock Price Analysis and Quick Research Report. Is Cipla an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Cipla and its performance over the period of time. Cipla stock price today is Rs 1507.7.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Cipla cash from the operating activity was Rs 3726.77 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Cipla has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Cipla , the EPS growth was 73.1889 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Cipla has OPM of 27.0547726183969 % which is a good sign for profitability.
     
  • ROE: Cipla have a average ROE of 14.1415 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Cipla is Rs 1507.7. One can use valuation calculators of ticker to know if Cipla share price is undervalued or overvalued.
Last Updated on:
Brief about Cipla

Cipla Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Cipla Ltd. stands as a prominent Indian pharmaceutical company with a strong global presence. This article offers a comprehensive analysis of Cipla's stock through the lens of a long-term investor. Key topics covered include insights on share price trends, balance sheet evaluation, annual report highlights, dividend performance, quarterly results analysis, stock price movements, price chart analysis, latest news updates, earnings conference call transcripts, investor presentations overview, details about promoters, and an overview of key shareholders.

Cipla Ltd. Share Price:

The share price of Cipla signifies a pivotal gauge of investor sentiment towards the company. It is influenced by multiple factors, including the company's financial performance, global economic conditions, and market sentiment. For long-term investors, our pre-built screening tools offer a valuable means to analyze Cipla's share price comprehensively, facilitating the identification of any discernible trends or patterns. Notably, the company's share price has exhibited a consistent upward trajectory in recent years, reflecting Cipla's robust financial performance and promising growth prospects.

Cipla Ltd. Balance Sheet:

Cipla's balance sheet provides crucial information about its financial health. The company's assets include research and development facilities, manufacturing facilities, and other fixed assets, while liabilities include borrowings and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Cipla's balance sheet and identify any red flags. The company's balance sheet has remained strong over the past few years, reflecting the company's low debt levels and strong operating cash flows. 

CIPLA Reserves

CIPLA has established high growth in total reserves where it has grown from ?17,241.71 crores in March 2020 to ?27,812.45 crores in March 2024. This significant increase reflects certain very good profit retention strategies coupled with provision of adequate capital to fund the growth of the business which is healthy.

CIPLA Debt Position

The balance sheets further show that CIPLA has no borrowing, which is captured by borrowings at ?0 in all the periods. It shows that the practice of financing is rather cautious that in turn points to lower levels of financial risk and improved stability of the company.

CIPLA Assets Growth

The Total assets of CIPLA has been in a progressive range from the fiscal ended 31st March 2020 to the fiscal ended 31st March, 2024. More revealing is the increase in investments from ?6,355.32 crores to ?9,410.17 crores which clearly shows serious efforts to expand its product line as well as its market niche.

CIPLA Current Assets

The current assets also show a climb from ?9,024.72 crores for Mar 2020 to ?14,857.84 crores for Mar 2024. As seen in the formula, growth of current assets increases the company’s liquidity position, thus making CIPLA more capable of discharging short term obligations and other cash related requirements.

This analysis sums up the Standalone Balance Sheet of CIPLA. The investors also need to consider changes in the pharmaceutical industry and the effects on market indexes of NSE AND BSE.

Cipla Ltd. Annual Report:

Cipla releases an annual report that provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Cipla's annual report from Ticker and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Cipla Ltd. Dividend:

Cipla has a consistent dividend history. The company has paid dividends every year, reflecting its commitment to rewarding shareholders. Long-term investors should consider this when evaluating Cipla's stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Cipla Ltd. Quarterly Results:

Cipla releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Cipla's quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Cipla Ltd. Stock Price:

The stock price of Cipla is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Cipla's stock price and identify potential buying opportunities. The stock price of Cipla has shown a steady upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Cipla Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Cipla's price chart and identify any trends or patterns. The price chart shows that the stock price of Cipla has shown a steady upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Cipla Ltd. News:

Keeping up to date with the latest news about Cipla is important for investors. Our website provides the latest news about Cipla from various sources, such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Cipla Ltd. Concall:

Cipla holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Cipla's concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Cipla Ltd. Transcripts:

Our website offers transcripts of Cipla's concalls. Long-term investors can download the transcripts and analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Cipla Ltd. Investor Presentations:

Cipla provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Cipla's investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Cipla Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Cipla's promoters include the founding family and institutional investors. Long-term investors can use our pre-built screening tools to analyze Cipla's promoter holdings and identify any potential conflicts of interest. The promoter holdings of Cipla are relatively stable, which is a positive sign for long-term investors.

Cipla Ltd. Shareholders:

Cipla has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Cipla's shareholder base and identify any potential risks or opportunities. The shareholder base of Cipla is diverse, which is a positive sign for long-term investors.

Cipla Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Cipla Limited ROCE

Cipla Limited ROCE (Return on Capital Employed) represents the company's ability to generate profits from the capital invested in its business. This ratio considers both equity and debt in the calculation and helps an investor evaluate the efficiency of a company's investment in its operations. You can get the ROCE data for Cipla Limited on this stock analysis page in the financials table or ratio section.

Cipla Limited EBITDA

Cipla Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a profitability metric that measures the company's operating performance. It reflects cash flow generated from the business operations, excluding non-operating expenses such as interest, taxes, depreciation, and amortization. Investors can use EBITDA as a metric to compare companies that operate in the same industry. You can find the EBITDA data for Cipla Limited on this stock analysis page within the financials or ratio section.

Cipla Limited DPS

Cipla Limited DPS (Dividend Per Share) is a metric that indicates the amount of dividend a company pays to its shareholders per share of stock they own. A consistently high DPS indicates a financially stable company that is returning value to its shareholders. Additionally, changes in DPS can provide insights into the company's financial status and future growth prospects. You can access the DPS data for Cipla Limited on this stock analysis page in the financials or ratio section.

Cipla Limited EPS

Cipla Limited EPS (Earnings Per Share) is a metric that indicates the amount of profit generated by the company per share of outstanding common stock. It provides insights into the company's profitability on a per-share basis and can help investors evaluate a company's growth potential. A high EPS usually indicates a fundamentally sound company with a strong financial position. This stock analysis page provides data on Cipla Limited's EPS within the financials or ratio section.

Cipla Revenue Analysis for Q2 FY25

According to the report, total net income for Q2 FY25 or the time period up to September 2024 was Rs 4,775.03 crore from the net sale of products. This has seen a robust increase of 12.8% from Rs 4,234.44 crore in Q2 FY24 and is 6.1% up from Rs 4,501.05 crore in Q1 FY25 indicating that there is constant demand and growth in the pharma sector.

Cipla Operating Profit Trends for Q2 FY25

The net operating revenue of the company also increased up to Rs 1,11,438.04 crore from Rs 94,225.38 crore in Q2 FY25 & Q2 FY24 respectively signifying operational leverage. It recorded an increase of 5.8% in the operating profit from Rs 1,359.86 crore it reflected during the Q1 FY25,

Profit and EPS performance of Cipla  for Q2 FY25

PAT in Q2 FY25 was Rs 1,178.16 crore which was 28.7 % higher than Rs 915.54 crore in Q2 FY24. Equally, and moreover, the PAT also increased by 11.5percent reaching Rs 1,117.93 crore from Rs 1,055.94 crore in Q1 FY25. The diluted EPS has been higher at Rs 13.28 in Q2 FY25 against Rs 10.99 in Q2 FY24 and the adjusted EPS was Rs 14.59 against Rs 11.34 in Q2 FY25 and Q2 FY24 respectively implying better per – share earnings.

Other Income and Expenses of Cipla for Q2 FY25

Other income for Q2 FY25 was Rs 289.14 crore against Rs 205.09 crore in Q2 FY24. Another savings Cipla was able to realize for Q2 FY25 was reductions in interest expenses that declined to Rs 3 crore compared to Rs 6.61 crore in Q2 FY24.

These figures are Cipla’s standalone numbers for the quarter. NSE and BSE indices within the pharmaceutical sector may be followed for tracking fluctuations within the industry and where Cipla stands in comparison.

Read More
X